Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.
By attending this session, you will be able to:
Provide an overview of the orphan drug landscape by discussing growth and trends associated with the orphan drug pipeline.
Discuss key assumptions used in the actuarial modeling of orphan drugs, how these assumptions are developed, and how they impact healthcare spending.
Identify unique challenges that treatments of rare diseases when setting assumptions.
Discuss considerations for payers to proactively manage the impact of these therapies and where there are limitations.
Take part in a deeper discussion on this topic and more at Oysters, Beers & Large Claim Solutions on Tuesday, June 27, from 4:30-5:30 p.m. PT. This happy hour, featuring drinks and tasty Pacific Northwest oysters will include a discussion on the large claims impacts on the health care market.